Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

The Lancet
May 30, 2020 Volume 395 Number 10238 p1669-1738, e98-e100
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Ivan Fan-Ngai Hung, et al